Related Experiment Video
Updated: Jul 13, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Enterococci and streptococci
1Centre for Infectious Diseases, College of Medicine and Veterinary Medicine, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK. s.g.b.amyes@ed.ac.uk
Abstract:
Besides Staphylococcus aureus, other Gram-positive bacteria have become multidrug-resistant and cause therapeutic problems, particularly amongst hospitalised patients. The acquisition of vancomycin resistance by strains of Enterococcus faecium and Enterococcus faecalis is of particular concern and has resulted in treatment failures. Some of the infections caused by these bacteria do respond to treatment with new antibiotics that have been released in the last few years, however more options are required as not all enterococci are inherently susceptible and resistance is beginning to emerge amongst those that were susceptible. Resistance to commonly used antibiotics is also emerging in Streptococcus spp., particularly to the tetracyclines and macrolides. In both genera, multiresistant strains spread between patients and between hospitals. In the laboratory, these bacteria show considerable susceptibility to tigecycline, with little propensity to develop resistance, indicating that tigecycline could assume an important role in controlling infections caused by these Gram-positive bacteria.
Insights
Multidrug-resistant Gram-positive bacteria, including enterococci and streptococci, pose significant treatment challenges. Tigecycline demonstrates broad in vitro susceptibility, suggesting its potential role in managing these difficult-to-treat infections.
Area of Science:
- Clinical microbiology
- Infectious diseases
- Antimicrobial resistance
Background:
- Emergence of multidrug-resistant (MDR) Gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, and Streptococcus spp., presents significant therapeutic challenges.
- Vancomycin resistance in enterococci is a particular concern, leading to treatment failures.
- Increasing resistance to common antibiotics like tetracyclines and macrolides is observed in Streptococcus spp.
Purpose of the Study:
- To evaluate the in vitro susceptibility of multidrug-resistant Gram-positive bacteria to tigecycline.
- To assess the potential of tigecycline as a therapeutic option for infections caused by these resistant pathogens.
Main Methods:
- In vitro susceptibility testing of clinical isolates of Gram-positive bacteria, including enterococci and streptococci, against tigecycline.
- Assessment of the propensity for resistance development to tigecycline in laboratory settings.
Main Results:
- Multidrug-resistant strains of Enterococcus spp. and Streptococcus spp. showed considerable in vitro susceptibility to tigecycline.
- Limited propensity for resistance development to tigecycline was observed in these bacterial groups.
- Tigecycline represents a potential treatment option for infections caused by vancomycin-resistant enterococci and other MDR Gram-positive bacteria.
Conclusions:
- Tigecycline exhibits promising in vitro activity against a range of multidrug-resistant Gram-positive bacteria.
- The low propensity for resistance development suggests tigecycline could play a crucial role in combating challenging Gram-positive infections.
- Further clinical evaluation is warranted to confirm the efficacy of tigecycline in treating infections caused by these resistant pathogens.
Related Concept Videos
Bacterial Phylum Actinobacteria
Microbiota of the Respiratory Tract
Microbiota of the Urogenital Tract
Mechanism of Antibiotic Resistance in MRSA
Staphylococcal Skin Infections
Clinical Significance of Antibiotic Resistance
